{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:39:35Z","timestamp":1770896375807,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2024-JYB-XJSJJ019"],"award-info":[{"award-number":["2024-JYB-XJSJJ019"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Project of Think Tanks of Universities in Heilongjiang of China","award":["ZKKF2022089"],"award-info":[{"award-number":["ZKKF2022089"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-026-26216-8","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:33:16Z","timestamp":1768818796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic evidence for expansion of HPV vaccination for the prevention of cervical cancer in LMICs: BIA framework construction and empirical analysis in China"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8449-6522","authenticated-orcid":false,"given":"Yi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-1416","authenticated-orcid":false,"given":"Liangru","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1383-9617","authenticated-orcid":false,"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"26216_CR1","unstructured":"WHO, Cervical Cancer. 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cervical-cancer. Accessed 15 Jan 2025."},{"key":"26216_CR2","volume-title":"Global burden of disease study 2019 (GBD 2019) results","author":"Global Burden of Disease Collaborative Network","year":"2020","unstructured":"Global Burden of Disease Collaborative Network. Global burden of disease study 2019 (GBD 2019) results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020."},{"key":"26216_CR3","volume-title":"Global strategy to accelerate the elimination of cervical cancer as a public health problem","author":"WHO","year":"2020","unstructured":"WHO. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020."},{"key":"26216_CR4","unstructured":"WHO. Introduction of HPV (Human Papilloma Virus) vaccine. 2023. https:\/\/immunizationdata.who.int\/pages\/vaccine-intro-by-antigen\/hpv.html?ISO_3_CODE=&YEAR=&CODE=High%20income. Accessed 18 July 2023."},{"issue":"1","key":"26216_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis\u2014Principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5\u201314. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00187.x.","journal-title":"Value Health"},{"issue":"12","key":"26216_CR6","doi-asserted-by":"publisher","first-page":"e0260808","DOI":"10.1371\/journal.pone.0260808","volume":"16","author":"KL Rosettie","year":"2021","unstructured":"Rosettie KL, Joffe JN, Sparks GW, et al. Cost-effectiveness of HPV vaccination in 195 countries: a meta-regression analysis. PLoS ONE. 2021;16(12):e0260808. https:\/\/doi.org\/10.1371\/journal.pone.0260808.","journal-title":"PLoS ONE"},{"issue":"4","key":"26216_CR7","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/ijc.33233","volume":"148","author":"EA Burger","year":"2021","unstructured":"Burger EA, Portnoy A, Campos NG, et al. Choosing the optimal HPV vaccine: the health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries. Int J Cancer. 2021;148(4):932\u201340. https:\/\/doi.org\/10.1002\/ijc.33233.","journal-title":"Int J Cancer"},{"issue":"Suppl 1","key":"26216_CR8","doi-asserted-by":"publisher","first-page":"A85","DOI":"10.1016\/j.vaccine.2021.07.027","volume":"40","author":"E Vodicka","year":"2022","unstructured":"Vodicka E, Nonvignon J, Antwi-Agyei KO, et al. The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana. Vaccine. 2022;40(Suppl 1):A85\u201393. https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.027.","journal-title":"Vaccine"},{"issue":"3","key":"26216_CR9","doi-asserted-by":"publisher","first-page":"e0230359","DOI":"10.1371\/journal.pone.0230359","volume":"15","author":"D Setiawan","year":"2020","unstructured":"Setiawan D, Andrijono, Hadinegoro SR, et al. Cervical cancer prevention in indonesia: an updated clinical impact, cost-effectiveness and budget impact analysis. PLoS ONE. 2020;15(3):e0230359. https:\/\/doi.org\/10.1371\/journal.pone.0230359.","journal-title":"PLoS ONE"},{"key":"26216_CR10","unstructured":"WHO. Cancer today. 2024. http:\/\/gco.iarc.fr\/today\/home. Accessed 14 Jan 2025."},{"issue":"10","key":"26216_CR11","doi-asserted-by":"publisher","first-page":"e1335","DOI":"10.1016\/S2214-109X(20)30277-1","volume":"8","author":"Z Zou","year":"2020","unstructured":"Zou Z, Fairley CK, Ong JJ, et al. Domestic HPV vaccine price and economic returns for cervical cancer prevention in china: a cost-effectiveness analysis. Lancet Global Health. 2020;8(10):e1335\u201344. https:\/\/doi.org\/10.1016\/S2214-109X(20)30277-1.","journal-title":"Lancet Global Health"},{"key":"26216_CR12","doi-asserted-by":"publisher","first-page":"763564","DOI":"10.3389\/fmed.2021.763564","volume":"8","author":"ZH Ye","year":"2021","unstructured":"Ye ZH, Liu ZZ, Cui ST, et al. High human papillomavirus vaccine acceptability and cost-effectiveness of the Chinese 2-valent vaccine among men who have sex with men: a cross-sectional study in Shenyang, China. Front Med (Lausanne). 2021;8:763564. https:\/\/doi.org\/10.3389\/fmed.2021.763564.","journal-title":"Front Med (Lausanne)"},{"key":"26216_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.863748","author":"L Zhou","year":"2022","unstructured":"Zhou L, Gu B, Xu X, et al. On imported and domestic human papillomavirus vaccines: cognition, attitude, and willingness to pay in Chinese medical students. Front Public Health. 2022. https:\/\/doi.org\/10.3389\/fpubh.2022.863748. 10.","journal-title":"Front Public Health"},{"issue":"5","key":"26216_CR14","first-page":"40","volume":"17","author":"DC Zhou","year":"2022","unstructured":"Zhou DC, Ma AX. Analysis of the feasibility of human papillomavirus vaccine included in the immunization program based on economic evidence. China J Pharm Econ. 2022;17(5):40\u20135. [in Chinese].","journal-title":"China J Pharm Econ"},{"key":"26216_CR15","unstructured":"National People\u2019s Congress of the People\u2019s Republic of China. Vaccine Administration Law of the People\u2019s Republic of China. 2019. https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/flxzhfg\/20190702121701506.html. Accessed 8 Dec 2023."},{"key":"26216_CR16","unstructured":"Human Resources and Social Security Bureau of Shenzhen Municipality. The Catalogue of Vaccine and Related Biological Products Reimbursed by Personal Medical Accounts of Insured Employees (Revised in 2018). 2018. http:\/\/hrss.sz.gov.cn\/xxgk\/qtxx\/tzgg\/content\/post_2053905.html. Accessed 16 Jul 2023."},{"issue":"1","key":"26216_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1186\/s12889-022-13056-5","volume":"22","author":"L Zhou","year":"2022","unstructured":"Zhou L, Gu B, Wang J, Liu G, Zhang X. Human papillomavirus vaccination at the National and provincial levels in china: a cost-effectiveness analysis using the PRIME model. BMC Public Health. 2022;22(1):777. https:\/\/doi.org\/10.1186\/s12889-022-13056-5.","journal-title":"BMC Public Health"},{"key":"26216_CR18","unstructured":"National Medical Products Administration in China. At what age is the vaccine suitable for cervical cancer?. 2019. https:\/\/www.nmpa.gov.cn\/xxgk\/kpzhsh\/kpzhshyp\/20190718120001220.html. Accessed 13 Jul 2023."},{"key":"26216_CR19","unstructured":"National Health Commission of the People\u2019s Republic of China. The action plan to accelerate the elimination of cervical cancer in China (2023\u20132030). 2023. http:\/\/www.nhc.gov.cn\/cms-search\/xxgk\/getManuscriptXxgk.htm?id=42c2c95b6db84f9cb356cfdf1edbbac7. Accessed 21 Apr 2023."},{"key":"26216_CR20","unstructured":"National Institutes for Food and Drug Control in China. Batch Release Biological Products. 2023. https:\/\/www.nifdc.org.cn\/nifdc\/xxgk\/ggtzh\/jwgk\/shwzhppfgg\/index.html. Accessed 13 July 2023."},{"issue":"5","key":"26216_CR21","first-page":"570","volume":"27","author":"YF Song","year":"2021","unstructured":"Song YF, Liu XX, Yin ZD, et al. Human papillomavirus vaccine coverage among the 9-45-year-old female population of China in 2018\u20132020. Chin J Vaccines Immun. 2021;27(5):570\u20135. [in Chinese].","journal-title":"Chin J Vaccines Immun"},{"key":"26216_CR22","unstructured":"National Bureau of Statistics of China. National Data. 2023. https:\/\/data.stats.gov.cn\/easyquery.htm?cn=C01. Accessed 28 June 2023."},{"key":"26216_CR23","unstructured":"IARC Information Centre on HPV and Cancer. Human Papillomavirus and related diseases in China. 2023. https:\/\/hpvcentre.net\/statistics\/reports\/CHN.pdf?t=1682056025029. Accessed 21 Apr 2023."},{"issue":"6","key":"26216_CR24","doi-asserted-by":"publisher","first-page":"2132802","DOI":"10.1080\/21645515.2022.2132802","volume":"18","author":"H Fang","year":"2022","unstructured":"Fang H, Chen C, Fang Y, et al. A guideline for economic evaluations of vaccines and immunization programs in China. Hum Vaccin Immunother. 2022;18(6):2132802. https:\/\/doi.org\/10.1080\/21645515.2022.2132802.","journal-title":"Hum Vaccin Immunother"},{"issue":"Suppl 5","key":"26216_CR25","doi-asserted-by":"publisher","first-page":"F29","DOI":"10.1016\/j.vaccine.2008.05.069","volume":"26","author":"E Su\u00e1rez","year":"2008","unstructured":"Su\u00e1rez E, Smith JS, Bosch FX, et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine. 2008;26(Suppl 5):F29\u201345. https:\/\/doi.org\/10.1016\/j.vaccine.2008.05.069.","journal-title":"Vaccine"},{"key":"26216_CR26","doi-asserted-by":"publisher","unstructured":"Praditsitthikorn N, Teerawattananon Y, Tantivess S, et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. PharmacoEconomics. 2011;29(9). https:\/\/doi.org\/10.2165\/11586560-000000000-00000.","DOI":"10.2165\/11586560-000000000-00000"},{"key":"26216_CR27","doi-asserted-by":"publisher","unstructured":"Jiang Y, Ni W, Wu J. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in china: an economic modelling analysis. BMJ Open. 2019;9(11). https:\/\/doi.org\/10.1136\/bmjopen-2021-052682.","DOI":"10.1136\/bmjopen-2021-052682"},{"issue":"7","key":"26216_CR28","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2214-109X(14)70237-2","volume":"2","author":"M Jit","year":"2014","unstructured":"Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014;2(7):e406\u2013414. https:\/\/doi.org\/10.1016\/S2214-109X(14)70237-2.","journal-title":"Lancet Glob Health"},{"key":"26216_CR29","doi-asserted-by":"crossref","unstructured":"National Bureau of Statistics of China. China Statistical Yearbook. (2020). 2020. https:\/\/www.stats.gov.cn\/sj\/ndsj\/2019\/indexch.htm. Accessed 11 Feb 2024.","DOI":"10.70190\/jq.I84.p154"},{"key":"26216_CR30","doi-asserted-by":"publisher","first-page":"e8152","DOI":"10.7717\/peerj.8152","volume":"7","author":"L Li","year":"2019","unstructured":"Li L, Zheng Z, Li L. Evaluation of human-papillomavirus screening for cervical cancer in china\u2019s rural population. PeerJ. 2019;7:e8152. https:\/\/doi.org\/10.7717\/peerj.8152.","journal-title":"PeerJ"},{"key":"26216_CR31","unstructured":"Xinhua. China to extend women\u2019s access to cervical, breast cancer screenings.2022. http:\/\/www.gov.cn\/xinwen\/2022-01\/18\/content_5669195.htm. Accessed 21 Apr 2023."},{"key":"26216_CR32","unstructured":"National Medical Insurance Administration. Statistical Communiqu\u00e9 on the Development of National Medical Security. (2019). 2020. http:\/\/www.gov.cn\/guoqing\/2020-03\/30\/content_5507506.htm. Accessed 25 Apr 2023."},{"key":"26216_CR33","unstructured":"National Medical Insurance Administration. Statistical Communiqu\u00e9 on the Development of National Medical Security. (2020). 2021. http:\/\/www.nhsa.gov.cn\/art\/2021\/6\/8\/art_7_5232.html. Accessed 25 Apr 2023."},{"key":"26216_CR34","unstructured":"National Medical Insurance Administration. Statistical Communiqu\u00e9 on the Development of National Medical Security. (2021). 2022. http:\/\/www.nhsa.gov.cn:8000\/art\/2022\/6\/8\/art_7_8276.html. Accessed 25 Apr 2023."},{"key":"26216_CR35","unstructured":"National Medical Insurance Administration. Statistical Communiqu\u00e9 on the Development of National Medical Security. (2022). 2023. http:\/\/www.nhsa.gov.cn\/art\/2023\/3\/9\/art_7_10250.html. Accessed 25 Apr 2023."},{"key":"26216_CR36","unstructured":"WHO. One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer. 2022. https:\/\/www.who.int\/news\/item\/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer. Accessed 15 Jan 2025."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-026-26216-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26216-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26216-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:00:21Z","timestamp":1770894021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-026-26216-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["26216"],"URL":"https:\/\/doi.org\/10.1186\/s12889-026-26216-8","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"585"}}